Immunofluorescence analyses revealed that these senescence markers and SLC25A26 had higher abundance in the HCC tissues of CTB-treated mouse compared to the model group, but interference with SLC25A26 impaired the effects of CTB (Fig. 7G). The gene discussed is SLC25A26; the disease is hepatocellular carcinoma.